Britannia Life Sciences Inc. (CSE:BLAB)
Canada · Delayed Price · Currency is CAD 0.0650
0.00 (0.00%)
Aug 7, 2026, 5:51 PM EST
Britannia Life Sciences Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 0.47 | 0.37 | 0.52 | 6.4 | 7.3 | |
Revenue Growth | 28.58% | -28.55% | -91.93% | -12.28% | 412.42% |
Cost of Revenue | 0.37 | 0.53 | 0.38 | 1.77 | 2.04 |
Gross Profit | 0.1 | -0.16 | 0.14 | 4.64 | 5.26 |
Selling, General & Admin | 1.5 | 1.99 | 1.46 | 2.59 | 2.54 |
Operating Expenses | 1.56 | 2.05 | 1.69 | 3.64 | 3.65 |
Operating Income | -1.46 | -2.22 | -1.55 | 0.99 | 1.62 |
Interest Expense | -0.03 | -0.11 | -0.1 | -0.85 | -2.31 |
Interest & Investment Income | 0.72 | - | - | - | - |
Earnings From Equity Investments | -1.91 | -2.09 | -0.96 | -0.02 | -0 |
Currency Exchange Gain (Loss) | 0.05 | -0.47 | -0.11 | -0.06 | 0.61 |
Other Non Operating Income (Expenses) | - | - | -3.82 | 4.41 | -3.22 |
EBT Excluding Unusual Items | -2.62 | -4.88 | -6.54 | 4.47 | -3.3 |
Impairment of Goodwill | - | - | -0.04 | - | - |
Gain (Loss) on Sale of Investments | 1.27 | - | - | - | - |
Gain (Loss) on Sale of Assets | 16.21 | 0.23 | 0.47 | 1.39 | - |
Other Unusual Items | -1.28 | 0.09 | - | - | -9.97 |
Pretax Income | 13.58 | -4.56 | -6.12 | 5.86 | -13.27 |
Income Tax Expense | 0.51 | - | - | 0.02 | 0.71 |
Earnings From Continuing Operations | 13.07 | -4.56 | -6.12 | 5.84 | -13.99 |
Earnings From Discontinued Operations | 1.58 | 12.07 | 1.72 | - | - |
Net Income to Company | 14.65 | 7.51 | -4.4 | 5.84 | -13.99 |
Minority Interest in Earnings | - | -0.11 | -0.37 | -0.75 | -1.47 |
Net Income | 14.65 | 7.39 | -4.77 | 5.08 | -15.46 |
Net Income to Common | 14.65 | 7.39 | -4.77 | 5.08 | -15.46 |
Net Income Growth | 98.18% | - | - | - | - |
Shares Outstanding (Basic) | 162 | 162 | 162 | 162 | 110 |
Shares Outstanding (Diluted) | 162 | 162 | 162 | 162 | 110 |
Shares Change | - | - | 0.07% | 48.07% | 41.06% |
EPS (Basic) | 0.09 | 0.05 | -0.03 | 0.03 | -0.14 |
EPS (Diluted) | 0.09 | 0.05 | -0.03 | 0.03 | -0.14 |
EPS Growth | 98.18% | - | - | - | - |
Free Cash Flow | -1.16 | -2.62 | 2.09 | 1.95 | 2.71 |
Free Cash Flow Per Share | -0.01 | -0.02 | 0.01 | 0.01 | 0.03 |
Gross Margin | 21.41% | -44.37% | 26.65% | 72.43% | 72.08% |
Operating Margin | -306.82% | -599.98% | -299.60% | 15.52% | 22.13% |
Profit Margin | 3085.51% | 2001.95% | -922.51% | 79.39% | -211.76% |
Free Cash Flow Margin | -243.50% | -709.38% | 404.71% | 30.50% | 37.16% |
EBITDA | -1.39 | -2.16 | -1.42 | 1.1 | 1.75 |
EBITDA Margin | -293.59% | - | -275.67% | 17.25% | 24.02% |
D&A For EBITDA | 0.06 | 0.06 | 0.12 | 0.11 | 0.14 |
EBIT | -1.46 | -2.22 | -1.55 | 0.99 | 1.62 |
EBIT Margin | - | - | -299.60% | 15.52% | 22.13% |
Effective Tax Rate | 3.74% | - | - | 0.34% | - |